If you're looking for some new portfolio additions, then it could be worth looking at the ASX 200 blue-chip shares listed below that have recently been named as buys.
Here's why analysts are positive on these top shares:
Image source: Getty Images
CSL Limited (ASX: CSL)
The first ASX 200 blue chip share that could be a buy is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring, CSL Vifor, and Seqirus businesses. These businesses collectively have a portfolio of world-class, life-saving therapies and vaccines. But CSL doesn't settle for that. Each year it invests 10% to 11% of its sales back into research and development (R&D) activities. This means the company has a large number of potentially lucrative therapies under development to support its future growth.
Citi is positive on CSL and has a buy rating rating and a $325 price target on its shares. This suggests an over 20% upside from current levels.
ResMed Inc. (ASX: RMD)
Another ASX 200 blue chip share that could be a buy is ResMed.
It is a medical device company involved in the development, manufacturing, distribution and marketing of products and cloud-based software applications that diagnose, treat and manage respiratory disorders. These include sleep-disordered breathing, chronic obstructive pulmonary disease, (COPD), neuromuscular disease, and other chronic diseases.
Morgans is a fan of ResMed and has an add rating and a $36.95 price target on its shares. This implies a potential upside of over 40%.
Woolworths Limited (ASX: WOW)
A final ASX 200 blue chip share that could be a buy is Woolworths. It is the retail giant behind the Woolworths supermarket chain and other brands such as Countdown and Big W.
Goldman Sachs is a big fan of the company. It believes Woolworths is well-placed to grow its market share thanks to its loyalty program and omnichannel advantage.
The broker has a conviction buy rating and a $42.20 price target on its shares. This suggests that Woolworths' shares could rise over 13% from current levels. Goldman also expects ~3% dividend yields through to FY 2025.
